News

The BIM-IOL System is for the treatment of elevated IOP in patients with mild-to-moderate open-angle glaucoma (OAG) or ocular hypertension (OHT).

Ophthalmologists discuss how advanced imaging, MIGS, and home monitoring are reshaping decision-making in complex glaucoma cases.

This retrospective cohort study used a large US administrative claims database to identify patients with a diagnosis of seborrheic dermatitis from January 1, 2016, through June 30, 2022.

Anat Loewenstein, MD, discusses the transformative impact of home OCT and AI on monitoring retinal diseases at AAO 2025.

Ophthalmologists weigh in on evolving diagnostic tools, emerging therapies, and practical approaches for managing today’s most challenging ocular-surface cases.

Under the terms of the agreement, 4DMT will grant Otsuka exclusive rights to develop and commercialize 4D-150 for retinal vascular diseases in Japan, China, Australia, and other Asia-Pacific markets.

Catch up on this week's highlights in retina.

Discover the latest advancements in laser vision correction, including next-gen LASIK techniques that achieve unprecedented visual outcomes.

Surgeons reflect on milestones that have redefined patient care—and share a glimpse of the advances that promise to shape the next era of eye health.

Harpal Sandhu, MD, FRCSC, discusses the preclinical performance of XPK-640 and how Optigo’s hyaluronic acid-anchoring platform may reshape dosing expectations in retinal disease.

The company describes KSI-101 as a “novel, potent, and high-strength (100 mg/mL) antibody-based investigational therapy with a bispecific mechanism of action targeting both interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF).”

OPGx-LCA5 is designed to address a form of Leber congenital amaurosis that results from biallelic mutations in the LCA5 gene, which encodes the lebercilin protein, the investigators explained.

It seems there is no text provided for summarization. Please provide the text you'd like summarized, and I'll be happy to help!

Karolinne M. Rocha, MD, PhD, shares advancements in vision correction and patient satisfaction at the AAO 2025 meeting.

PolyActiva and RareSight collaborate to create innovative therapies for rare pediatric retinal diseases, aiming to transform treatment and improve children's vision.

Tsu Shan Chambers shares how the film "My Eyes" uses authentic storytelling to raise awareness of inherited eye disease and the importance of preventive vision care.

Marking 5 decades of Ophthalmology Times, clinicians share the innovations that defined their training, shaped patient outcomes, and continue to push the field ahead.

The EXTEND trial provided 5-year follow-up for 10 patients with advanced retinitis pigmentosa, who had previously received MCO-010 during a phase 1/2a trial

The trial is evaluating 4D-150 in patients with wet age-related macular degeneration (wet AMD).

Host Deborah Ristvedt, DO, is joined by Marguerite B. McDonald, MD, FACS, to discuss her journey with pioneering contributions to ophthalmology, patient-centered care, leadership, and guidance for the next generation.

Johnson & Johnson reaches 100,000 TECNIS ODYSSEY IOLs implanted, and presented data on in vision correction and patient satisfaction at the AAO 2025 meeting.

Data suggests that EYP-1901 can reduce the number of injections and treatment burden for patients

A mutation-agnostic gene therapy approach offers new possibilities for patients, especially those with inherited retinal diseases.

The VITA Trial is a prospective pilot study on the VisiPlate Aqueous Shunt in patients with with open-angle glaucoma.

The addition comes as the company accelerates development of its long-acting anti-VEGF program and advances its HA-binding platform.